Immune checkpoint inhibitors (ICIs) orchestrate the body's innate immune system by blocking inhibitory signals between immune cells and cancer cells.[1] Since the approval of the first ICI, ipilimumab, the U.S. Food and Drug Administration (FDA) has approved ten ICIs, each showing therapeutic benefit across multiple malignancies.[2] Among various immune checkpoint molecules, programmed cell death protein‐1 (PD‐1) and its counter ligand, programmed cell death‐ligand 1 (PD‐L1), are the most well‐established targets for immune checkpoint inhibition. The gene discussed is CD274; the disease is cancer.